STAT

STAT+: Pharmalittle: We’re reading about Wegovy insurance coverage, Zepbound shortages, and more

The first major U.S. health insurers have agreed to start paying for the Wegovy weight loss drug for certain people on Medicare with heart conditions.
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still being formulated, but we do hope to promenade with the official mascots, catch, , and . And what about you? Spring has sprung, so this is an invitation to enjoy the great outdoors — perhaps a walk in the woods or a stroll down city streets is in order. This is also fine time to tidy up and clear out your castle. If you prefer to look ahead, you could plan a summer getaway or, if ambition overcomes you, maybe the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks